QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=7B1F6693B270947344DE4E5335DCA1D3;jsessionid=377AA20F3F2C7040DFFDB9EF090E8E80;jsessionid=5DEF7EFA4D41072573B10DCEBD2987D4;jsessionid=5766FD34954C857A467E0F37C2A3278D;jsessionid=C72A5F5CA71B9A8F4CE910900584CEE5;jsessionid=F6102464D2544CC611AC6CE645C2D7E3;jsessionid=FA9E51B2A4C2A48C4DCDE17DEF84FD0B;jsessionid=3F447D38B91D146C3DC787E4CAA1262C (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=7B1F6693B270947344DE4E5335DCA1D3;jsessionid=377AA20F3F2C7040DFFDB9EF090E8E80;jsessionid=5DEF7EFA4D41072573B10DCEBD2987D4;jsessionid=5766FD34954C857A467E0F37C2A3278D;jsessionid=C72A5F5CA71B9A8F4CE910900584CEE5;jsessionid=F6102464D2544CC611AC6CE645C2D7E3;jsessionid=FA9E51B2A4C2A48C4DCDE17DEF84FD0B;jsessionid=3F447D38B91D146C3DC787E4CAA1262C